NCT00338182

AZD1152 in Patients With Advanced Solid Malignancies

A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1152 Given as a 2-hour or 48-hour Intravenous Infusions in Patients With Advanced Solid Malignancies

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 43 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years – 130 Years
• Healthy volunteers: Not accepted

Summary

The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152 when given as a continuous 48-hour infusion every 14 days and as a 2-hour infusion for 2 consecutive days every 14 days in patients with advanced solid malignancies.

Conditions

• Tumors

Interventions

Type	Name	Description
DRUG	AZD1152 part A	48-hour continuous intravenous infusion
DRUG	AZD1152 part B	2-hour intravenous infusion

Timeline

• Start date: 2006-05-23
• Primary completion: 2008-06-06
• Completion: 2017-03-01
• First posted: 2006-06-20
• Last updated: 2017-04-24

Locations

2 sites across 1 country: United States